Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 1

First line targeted therapies in breast cancer: focus on bevacizumab || FREE PAPER ||

Authors Amalia Milano, Gugliemo Nasti, Rosario Vincenzo Iaffaioli, Francesco Caponigro

Published 15 August 2007 Volume 2007:1(1) Pages 3—10

Amalia Milano, Gugliemo Nasti, Rosario Vincenzo Iaffaioli, Francesco Caponigro

Istituto Nazionale Tumori “Fondazione G. Pascale” Via M. Semmola, 80131 Napoli, Italy

Abstract: The heterogeneity of metastatic breast cancer mandates the need to select therapies taking into account tumor and patient characteristics. Chemotherapy is indicated in the palliative setting especially when the disease is unresponsive to hormonal therapy or is hormone-receptor negative. The main chemotherapeutic agents are anthracyclines, taxanes, and capecitabine. The knowledge of the effects of currently approved agents and of the biology of breast cancer have paved the way for the evaluation of new treatment options, among which are anti-angiogenic agents. Angiogenesis inhibition has resulted in clinically significant improvements in the outcome of a variety of malignancies, including breast cancer. Bevacizumab, a monoclonal antibody anti-vascular endothelial growth factor (VEGF), is the most extensively studied antiangiogenic compound. According to the results of a phase III trial in patients with untreated metastatic breast cancer, bevacizumab increases both objective response rate and median progression-free survival when combined with standard chemotherapy vs chemotherapy alone. The combination of anti-angiogenic drugs and other biologic agents is also being explored in an attempt to improve efficacy.

Keywords: angiogenesis, bevacizumab, breast cancer, monoclonal antibody

Download Article [PDF] 

Readers of this article also read:

Accessing to the minor proteome of red blood cells through the influence of the nanoparticle surface properties on the corona composition

Zaccaria A, Roux-Dalvai F, Bouamrani A, Mombrun A, Mossuz P, Monsarrat B, Berger F

International Journal of Nanomedicine 2015, 10:1869-1883

Published Date: 9 March 2015

Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain

Tamaru M, Akita H, Nakatani T, Kajimoto K, Sato Y, Hatakeyama H, Harashima H

International Journal of Nanomedicine 2014, 9:4267-4276

Published Date: 8 September 2014

Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent [Corrigendum]

Park J, Cho W, Park HJ, Cha KH, Ha DC, Choi YW, Lee HY, Cho SH, Hwang SJ

International Journal of Nanomedicine 2014, 9:559-560

Published Date: 20 January 2014

Simple heuristics in over-the-counter drug choices: a new hint for medical education and practice

Silvia Riva, Marco Monti, Alessandro Antonietti

Advances in Medical Education and Practice 2011, 2:59-70

Published Date: 16 February 2011

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

Yvette RBM van Gestel, Sanne E Hoeks, Don D Sin, Henk Stam, Frans W Mertens, Jeroen J Bax, Ron T van Domburg, Don Poldermans

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:177-183

Published Date: 8 May 2009

The quality of caring relationships

Tineke A Abma, Barth Oeseburg, Guy AM Widdershoven, Marian Verkerk

Psychology Research and Behavior Management 2009, 2:39-45

Published Date: 10 March 2009

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008